SCHEMBL6783126

SCHEMBL6783126

CCCCOc1ccc(N(C)C(=O)CC2(O)CCN(C(=O)CCc3ccccc3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 2/20 0.51
ME1 P48163 2/20 0.51
ME3 Q16798 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 3/20 0.47
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
HRH2 P25021 1/20 0.44
HRH1 P35367 1/20 0.44
ALDH1A1 P00352 6/20 0.44
TDP1 Q9NUW8 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 2/20 0.42
USP7 Q93009 2/20 0.42
YAP1 P46937 1/20 0.41
USP19 O94966 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6782805 0.91 HRH2 (0.52) SMN1; SMN2NPC1RAB9AMAPTGAA
SCHEMBL6784044 0.88 KMT2A (0.51) L3MBTL1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6784170 0.85 KMT2A (0.54) SMN1; SMN2RAB9AALDH1A1TSHRMEN1
SCHEMBL6779964 0.82 SMN1; SMN2 (0.53) L3MBTL1SMN1; SMN2MAPTHRH2HRH1
SCHEMBL6785039 0.79 GPR119 (0.46) ALDH1A1TDP1
SCHEMBL6897762 0.78 HRH2 (0.42) HRH2HRH1MEN1KMT2A
SCHEMBL6783406 0.77 PKM (0.56) L3MBTL1SMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL6785222 0.77 MEN1 (0.47) SMN1; SMN2RAB9AMAPTALDH1A1TDP1
SCHEMBL6784066 0.77 HTR2A (0.47) HRH2HRH1ALDH1A1
SCHEMBL6901175 0.76 KMT2A (0.48) L3MBTL1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710060-B2 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-12-12 US disclosed
EP-1182192-A1 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity SCN5A, RYR2, SCN1B ME2 717/4885ME1 894/4885ME3 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.